Deutsche Bank AG Reiterates Hold Rating for Valeant Pharmaceuticals International, Inc. (VRX)

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “hold” rating reissued by Deutsche Bank AG in a research note issued on Monday. They presently have a $18.00 target price on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s target price would suggest a potential upside of 24.48% from the company’s current price.

VRX has been the topic of a number of other research reports. J P Morgan Chase & Co set a $10.00 target price on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Monday, July 17th. HC Wainwright reiterated a “hold” rating and set a $17.00 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, October 4th. Cantor Fitzgerald reiterated a “buy” rating and set a $23.00 target price on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Guggenheim began coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Wells Fargo & Company reiterated an “underperform” rating and set a $9.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Five analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have issued a buy rating to the stock. Valeant Pharmaceuticals International has a consensus rating of “Hold” and a consensus target price of $17.68.

Valeant Pharmaceuticals International (NYSE VRX) opened at 14.46 on Monday. Valeant Pharmaceuticals International has a 1-year low of $8.31 and a 1-year high of $24.30. The firm’s market cap is $5.04 billion. The firm’s 50-day moving average price is $14.02 and its 200-day moving average price is $13.51.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. The firm had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. Valeant Pharmaceuticals International’s quarterly revenue was down 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.88) EPS. On average, equities research analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/10/11/deutsche-bank-ag-reiterates-hold-rating-for-valeant-pharmaceuticals-international-inc-vrx.html.

In other news, Director Schutter Richard U. De bought 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The shares were purchased at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the acquisition, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.87% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the stock. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Valeant Pharmaceuticals International by 2.9% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 490,395 shares of the specialty pharmaceutical company’s stock valued at $8,509,000 after acquiring an additional 13,810 shares during the last quarter. Morgan Stanley boosted its holdings in Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock valued at $30,631,000 after acquiring an additional 903,256 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in Valeant Pharmaceuticals International by 61.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 41,414 shares of the specialty pharmaceutical company’s stock valued at $457,000 after acquiring an additional 15,719 shares during the last quarter. Legal & General Group Plc boosted its holdings in Valeant Pharmaceuticals International by 9.2% in the second quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock valued at $23,895,000 after acquiring an additional 121,032 shares during the last quarter. Finally, Paloma Partners Management Co boosted its holdings in Valeant Pharmaceuticals International by 12.0% in the first quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock valued at $310,000 after acquiring an additional 2,996 shares during the last quarter. Hedge funds and other institutional investors own 50.48% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

What are top analysts saying about Valeant Pharmaceuticals International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit